WO2009081716A1 - Grain sphérique, son procédé de fabrication et procédé pour produire d'une préparation à libération entretenue - Google Patents
Grain sphérique, son procédé de fabrication et procédé pour produire d'une préparation à libération entretenue Download PDFInfo
- Publication number
- WO2009081716A1 WO2009081716A1 PCT/JP2008/072169 JP2008072169W WO2009081716A1 WO 2009081716 A1 WO2009081716 A1 WO 2009081716A1 JP 2008072169 W JP2008072169 W JP 2008072169W WO 2009081716 A1 WO2009081716 A1 WO 2009081716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- central core
- spherical
- coating layer
- producing
- particle
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000003405 delayed action preparation Substances 0.000 title claims abstract description 14
- 239000013078 crystal Substances 0.000 claims abstract description 67
- 239000011247 coating layer Substances 0.000 claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 239000007771 core particle Substances 0.000 claims description 89
- 239000012798 spherical particle Substances 0.000 claims description 77
- 239000007788 liquid Substances 0.000 claims description 54
- 238000005096 rolling process Methods 0.000 claims description 37
- 238000005507 spraying Methods 0.000 claims description 20
- 239000013543 active substance Substances 0.000 claims description 17
- 238000005520 cutting process Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 abstract description 7
- 239000002245 particle Substances 0.000 description 31
- 239000000843 powder Substances 0.000 description 31
- 239000011248 coating agent Substances 0.000 description 29
- 238000000576 coating method Methods 0.000 description 29
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 21
- 239000008187 granular material Substances 0.000 description 18
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 16
- 235000002906 tartaric acid Nutrition 0.000 description 16
- 239000011975 tartaric acid Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 229930006000 Sucrose Natural products 0.000 description 12
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000021552 granulated sugar Nutrition 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 150000005846 sugar alcohols Chemical class 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CCGPUGMWYLICGL-UHFFFAOYSA-N Neburon Chemical compound CCCCN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 CCGPUGMWYLICGL-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000004083 gastrointestinal agent Substances 0.000 description 2
- 229940127227 gastrointestinal drug Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- -1 organic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002968 autonomic agent Substances 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
- A23P30/10—Moulding
Definitions
- the present invention relates to a spherical particle, a method for producing the same, and a method for producing a controlled release preparation.
- Controlled release is one of the techniques for keeping the physiologically active substance concentration-time pattern at the site of action of the physiologically active substance (drug) optimal.
- a controlled release formulation for realizing controlled release (Controlled Release formulation)
- the surface of a spherical particle for example, “Nonparel (registered trademark)” manufactured by Freund Sangyo Co., Ltd.
- the surface of a spherical particle is coated (layer) After filming, there is a film coated with a film substrate according to the purpose.
- This spherical particle for layering is required to be closer to the true sphere in order to accurately control the release rate of the physiologically active substance.
- the spherical particles for layering are manufactured by the following method, for example.
- particles serving as a central core (hereinafter referred to as central core particles) are rolled in various granulators, and a powder that is a main component of spherical particles is supplied thereto.
- it is granulated by spraying a liquid for wetting the central core particles and powder.
- the granulated particles are then dried to form spherical particles for layering.
- a granulated sugar crystal is charged as a central core particle in an operating centrifugal rolling device.
- fine particles or fine powder of sucrose is sprayed on the crystal while spraying an aqueous solution of sucrose as a binder.
- fine particles or fine powder of sucrose is coated on granulated sugar crystals and granulated into a spherical shape (see paragraph [0004] of Patent Document 1). JP 2004-67670 A
- the present invention has been made in view of the above circumstances, and an object thereof is a spherical particle having a small particle diameter and high sphericity while using central core particles made of crystal grains, and a method for producing the same. Furthermore, it aims at the manufacturing method of the controlled release formulation which uses this spherical particle.
- the spherical grain of the present invention is characterized in that a coating layer is fixed on the surface of the central core particle obtained by cutting the corner of the crystal grain.
- the method for producing a spherical grain of the present invention comprises a first step of cutting the corners of the crystal grains to form central core particles, and a second step of fixing a coating layer on the surface of the central core particles.
- the second step is a step of supplying a powdery coating layer forming component and spraying a liquid while rolling or flowing the central core particle to fix the coating layer on the surface of the central core particle.
- the second step is a step of spraying a liquid on the surface of the core core particles while rolling or flowing, and fixing the coating layer forming component dissolved or dispersed in the liquid to the core particles. preferable.
- the crystal grains comprise crystals of any of physiologically active substances that can be taken orally, pharmaceuticals, or food additives.
- the crystal grains are preferably made of sugar crystals.
- the crystal grains are preferably made of pharmaceutical crystals.
- the crystal grains are preferably made of organic acid crystals.
- the production method of the controlled-release preparation of the present invention is preferably a method in which a spherical particle obtained by the production method is layered with a component containing a physiologically active substance, and further film coating is performed.
- the method for producing spherical particles of the present invention it is possible to obtain spherical particles having a small particle diameter and high sphericity while using central core particles made of crystal grains. Further, the spherical particles of the present invention have a small particle diameter and a high sphericity. Therefore, when the spherical particles of the present invention are used when producing a controlled release preparation, a controlled release preparation having preferable release controllability can be obtained.
- the spherical grain of this embodiment is characterized in that a coating layer is fixed to the surface of the central core particle obtained by cutting the corner of the crystal grain.
- crystal grains used for the central core particles it is preferable to use crystals such as orally ingestible physiologically active substances, pharmaceuticals or food additives.
- crystals such as orally ingestible physiologically active substances, pharmaceuticals or food additives.
- the central core particles according to the present embodiment those obtained by cutting off the corners of these crystal grains are used.
- sugars such as glucose, fructose, sucrose, and lactose
- sugar alcohols such as mannitol, xylitol, and erythritol
- organic acids such as citric acid, tartaric acid, ascorbic acid, and sodium salts, calcium salts, and potassium salts thereof
- Salts Inorganic substances typified by inorganic salts such as salt; pharmaceuticals and health foods typified by ethenamide, aspirin, ephedrine and the like.
- sucrose, lactose, citric acid, and tartaric acid are preferably used.
- the spherical particle coating layer of the present embodiment is fixed to the surface of the central core particle.
- the term “fixed” refers to a state in which the coating layer is fixed to the surface of the central core particle using a liquid or the like so that a part of the coating layer is not taken off and scattered. Therefore, it is different from the one in which only the powder is adhered to the central core particle without using a liquid or the like.
- the spherical particles of the present embodiment are used as the central core of a controlled release preparation or the like, it is difficult for the coating layer to scatter or be lost.
- the coating layer forming component it is preferable to use pharmaceutical / food additives such as sugar, sugar alcohol, starches, organic acids, physiologically active substances that can be taken orally, film coating agents used for pharmaceuticals / food, and the like.
- film coating agent include cellulose derivatives such as methylcellulose (MC), ethylcellulose (EC), hydroxylpropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), and carboxymethylethylcellulose (CMEC); non-xanthan gum, locust bean gum and the like Cellulose polysaccharides; synthetic polymers such as polyethylene oxide, acrylic acid polymer, polyvinyl alcohol, and polyvinylpyrrolidone.
- the sphericity (minor axis / major axis) of the spherical particles of the present embodiment is preferably 0.85 or more.
- components containing a physiologically active substance can be more uniformly layered. Therefore, the release rate of the physiologically active substance in the controlled release preparation using the spherical particles can be controlled more accurately.
- the spherical grain manufacturing method of the present embodiment includes a first step of cutting the corners of the crystal grains to form central core particles, and a second step of fixing a coating layer on the surface of the central core particles. It is characterized by.
- the shape of the crystal grains used for forming the central core particles is not particularly limited, but a shape close to a cubic is preferable for spheroidization.
- the size of the crystal grains is preferably 50 ⁇ m or more and 1000 ⁇ m or less, more preferably 75 ⁇ m or more and 500 ⁇ m, as measured by a sieving method (hereinafter referred to as the particle size). More preferably, it is as follows. When the particle diameter of the crystal grains is larger than 1000 ⁇ m, it is difficult to use as a component of the preparation. If the crystal grain size is less than 50 ⁇ m, aggregation may occur in the second step of forming the coating layer.
- An apparatus having a stirring blade, a rotor, an agitator and the like can be used to cut the corners of the crystal grains.
- this apparatus include a stirring granulator (for example, a tabletop stirring granulator manufactured by Kawata Co., Ltd., SUPER MIXER, PICCOLO, etc.) and a combined fluidized bed granulation coating apparatus (for example, Freund Sangyo Co., Ltd.). Spiraflow made of). Conditions such as the number of rotations and movement time during operation of the apparatus are adjusted to such an extent that the corners of the crystal grains can be cut while observing the crystal grains.
- the second step of fixing the coating layer on the surface of the central core particle obtained in the first step include the following first and second modes.
- the first aspect is a step of fixing the coating layer on the surface of the central core particle by supplying a powdery coating layer forming component and spraying a liquid while rolling or flowing the central core particle.
- the second aspect is a step of fixing the coating layer forming component dissolved or dispersed in the liquid to the central core particles while spraying the liquid on the surface of the central core particles while rolling or flowing.
- a centrifugal rolling coating apparatus 10 of FIG. 1 includes a centrifugal rolling chamber 11 that granulates while rolling central core particles and the like.
- the centrifugal rolling chamber 11 includes a cylindrical fixed wall 12 disposed so that the axis is in the vertical direction, and a circular rotating tray 13.
- the rotating tray 13 is disposed inside the fixed wall 12 and rotates in the horizontal direction around the central axis 14 while leaving a predetermined clearance from the inner wall of the fixed wall 12.
- the centrifugal rolling coating apparatus 10 granulates a spherical shape by rolling central core particles and powders of components forming a coating layer on a rotating dish 13.
- the rotating dish 13 has a shape in which the peripheral edge is gradually inclined upward, and the powder can be uniformly rolled thereon. Further, a thermometer such as a thermocouple (not shown) is installed in the centrifugal rolling chamber 11 so that the particle temperature can be measured.
- a thermometer such as a thermocouple (not shown) is installed in the centrifugal rolling chamber 11 so that the particle temperature can be measured.
- the centrifugal rolling chamber 11 is provided with a powder supply tube (powder supply device) 15 from which the powder of the component forming the coating layer can be sprayed. Further, the centrifugal rolling chamber 11 is provided with a spraying device 16 so that a liquid containing a component that acts as a binder can be sprayed into the centrifugal rolling chamber 11 as necessary. Further, in this example, an air chamber 17 is formed below the rotating dish 13. By sending compressed air from the compressed air supply pipe 18 into the air chamber 17, high-pressure air (hereinafter referred to as slit air) from the clearance portion between the inner wall of the fixed wall 12 and the rotating dish 13 into the centrifugal rolling chamber 11. .) Is introduced. The mixing air circulation of the powder is further enhanced by the slit air.
- Reference numeral 19 in the drawing denotes an exhaust port.
- the apparatus having the same basic configuration as the centrifugal rolling coating apparatus shown in FIG. 1 include “CF granulator” and “Granurex” manufactured by Freund Corporation.
- the fluidized bed granulation coating apparatus examples include “Flow Coater” manufactured by Freund Sangyo Co., Ltd.
- the composite fluidized granulation coating apparatus can also be used for the first step as described above. Therefore, when a composite fluidized granulation coating apparatus is used, the first step and the second step can be continuously performed with one apparatus by appropriately setting conditions.
- a powdery coating layer forming component is introduced from the powder supply pipe 15 while rolling the central core particles on the rotating dish 13. If the diameter of the rotating dish 13 is about 360 mm, the rotating dish 13 is rotated at, for example, 100 rpm or more and 200 rpm or less.
- the liquid is sprayed from the spraying device 16 while introducing slit air into the centrifugal rolling chamber 11. In this way, the powdery coating layer forming component is granulated while being wetted.
- the powdery coating layer forming component is preferably introduced in an amount of 10 to 300 parts by mass, more preferably 10 to 120 parts by mass, with respect to 100 parts by mass of the central core particle. As described above, in this embodiment, it is possible to spheroidize with a smaller amount of the coating layer forming component as compared with the case where powder layering is performed without cutting the corners of the crystal grains. Therefore, in this embodiment, not only the process time can be shortened but also the yield can be expected.
- the particle diameter of the powdery coating layer forming component is not particularly limited, but is preferably a powder whose particle diameter is 1/10 or less of the diameter of the central core particle.
- the powdery coating layer-forming component among the coating layer-forming components, it is particularly preferable to use powders such as sugars, sugar alcohols, starches, pharmaceutical and food additives such as organic acids, or physiologically active substances that can be taken orally. preferable.
- binders include sugars, sugar alcohols, organic acids, cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate succinate, starches, polyvinylpyrrolidone, poly (meth) acrylic acid and esters thereof , Polyvinyl alcohol and derivatives thereof, and polyoxyethylene hydrogenated castor oil. These components may be used alone or in combination of two or more.
- a liquid is sprayed on the surface of the central core particles while rolling or flowing, and the coating layer forming component dissolved or dispersed in the liquid is fixed to the central core particles.
- This embodiment can also be implemented using a centrifugal roll coating apparatus 10 as shown in FIG.
- the central core particles are rolled on the rotating dish 13.
- liquid is sprayed from the spraying device 16 while introducing slit air into the centrifugal rolling chamber 11. And it granulates with the coating layer formation component melt
- the coating layer forming component that forms the coating layer may be dissolved or dispersed in a liquid to be sprayed in advance before spraying. Moreover, the coating layer forming component which forms a coating layer may be dissolved by the sprayed liquid after spraying. That is, as the liquid sprayed to form the coating layer of the present embodiment, the following three modes are exemplified.
- An organic solvent such as alcohol, and a mixed liquid of water and an organic solvent liquid C.
- the coating layer forming component it is preferable to use a component having a binder effect among the coating layer forming components.
- the thing without a binder effect or a thing with a weak binder effect can be used by using together with a coating layer formation component with a high binder effect.
- the concentration of the coating layer forming component in the solution is set near the solubility upper limit of the coating layer forming component.
- the concentration of the dispersoid may be appropriately set in consideration of viscosity, sprayability, and the like. Further, the dispersoid may be dispersed in (Liquid A).
- the liquid to be sprayed is a solution or dispersion containing the coating layer forming component in advance
- spherical particles are produced using the centrifugal rolling coating apparatus 10 by the following method.
- the central core particles are rolled on the rotating dish 13.
- the liquid containing the coating layer forming component is sprayed onto the central core particles rolling from the spraying device 16, and the coating layer is formed on the surface of the central core particles.
- the spherical particles of this embodiment are obtained by the above method.
- the liquid is a solution (liquid A)
- the abrasion resistance is improved, which is more preferable.
- liquid to be sprayed is (liquid C)
- (liquid C) is preferably allowed to act as a solvent for dissolving the fine powder (solute) of crystal grains generated in the first step after spraying.
- the centrifugal rolling coating apparatus 10 using the centrifugal rolling coating apparatus 10, first, the central core particles and the fine powder thereof are rolled on the rotating dish 13. Next, while introducing slit air into the centrifugal rolling chamber 11, (fine liquid C) is sprayed onto the fine powder from the spray device 16 as a solvent.
- the spray amount of (Liquid C) is an amount capable of dissolving the fine powder as the solute, and is appropriately adjusted according to the components.
- the spherical particles of the present embodiment obtained through the first step and the second step may be taken out of the centrifugal tumbling coating apparatus and then transferred to an apparatus such as a fluidized bed apparatus and dried. it can.
- the corners of the crystal grains serving as the central core particles are cut in advance, and then the coating layer is formed. Therefore, spherical particles having a sufficiently high sphericity can be obtained without forming a thick coating layer. Furthermore, the particle diameter of the spherical particles can be reduced. Further, when a liquid is used in forming the coating layer, voids are not easily generated in the coating layer, so that spherical particles having higher hardness than those obtained by powder layering can be obtained. Such spherical particles of the present embodiment can be used for medicines and the like because the control of release control is accurate when used in controlled release preparations and the like.
- the production method of the controlled-release preparation of this embodiment is preferably a method in which a spherical particle obtained by the production method is layered with a component containing a physiologically active substance, and then film coating is further performed.
- the spherical particles are formed of a component containing a physiologically active substance (drug), they can be used as drug particles or the like as they are.
- Spherical particle layering and film coating with a component containing a physiologically active substance, etc. is performed by centrifugal rolling granulation coating apparatus (for example, “CF Granulator”, “Granurex” manufactured by Freund Sangyo Co., Ltd.), flow, etc.
- a layer granulation coating apparatus for example, “Flow coater” manufactured by Freund Sangyo Co., Ltd.
- a composite granulation coating apparatus for example, “Spiraflow” manufactured by Freund Sangyo Co., Ltd.
- physiologically active substances include hypnotics / sedatives, antipyretic analgesics, antipsychotic agents, autonomic agents, antiparkinson agents, antihistamines, cardiotonic agents, diuretics, antihypertensive agents, vasoconstrictors, Arteriosclerotic agents, antitussive expectorants, vitamins, nourishing tonics, antibiotics, gastrointestinal drugs and the like.
- a film base suitable for the purpose such as release control or masking of a physiologically active substance, may be appropriately used.
- Example 1 Tartaric acid crystals (L-Tartaric acid S, manufactured by Fuso Chemical Industry Co., Ltd.) were put into a table type stirring granulator (manufactured by Kawata Co., Ltd., SUPER MIXER PICCOLO), stirred at 2500 rpm for 60 minutes, and the corners of the crystal were shaved. It was. Thereafter, the corner-cut crystals were sieved to obtain central core particles having a particle diameter of 180 ⁇ m or more and 250 ⁇ m or less.
- a table type stirring granulator manufactured by Kawata Co., Ltd., SUPER MIXER PICCOLO
- CF-360EX centrifugal rolling type coating granulator CF granulator
- an aqueous tartaric acid solution having a concentration of 50% by mass was added to the central core particles. It sprayed until the mass of the solid content of tartaric acid with respect to the mass of 100 became 100 mass%.
- spherical particles of tartaric acid having a sphericity of 0.90, a particle diameter of 212 ⁇ m or more and 355 ⁇ m or less were obtained in a yield of about 92%.
- the solid content means a component excluding moisture (the amount of dry matter obtained by subtracting moisture from the total amount).
- Example 2 A tartaric acid crystal having a particle diameter of 180 ⁇ m or more and 250 ⁇ m or less obtained by the same operation as in Example 1 was used as the central core particle.
- Centrifugal fluid coating granulator CF granulator was charged with 500 g of central core particles, and 500 g of L-tartaric acid S pulverized product was charged into the central core particles while spraying an aqueous tartaric acid solution having a concentration of 50% by mass onto the central core particles. .
- the core particles were powder layered.
- the spray amount of the tartaric acid aqueous solution was 180 g.
- spherical particles of tartaric acid having a sphericity of 0.90, a particle diameter of 212 ⁇ m or more and 355 ⁇ m or less were obtained in a yield of about 85%.
- the minor axis / major axis ratio is the ratio of the minor axis to the major axis of a spherical particle, and is a measure of sphericity.
- the ratio between the short axis and the long axis is determined by randomly placing spherical particles on the sample stage, taking a photograph, and measuring the length of the long axis (major axis) of the 50 spherical particles and the length of the short axis perpendicular to the midpoint of the long axis.
- the length (minor axis) is measured, the ratio of the minor axis to the major axis is determined for each, and the average value of 50 is shown.
- a yield is the value calculated
- the coating layer forming component is powdery or liquid. Both sphericities are excellent at 0.90.
- Comparative Example 1 and Comparative Example 2 using crystal grains that do not cut corners as the central core particles the sphericity is less than 0.85 regardless of whether the coating layer forming component is powdery or liquid. The desired sphericity was not obtained.
- Example 3 Crystals of granulated sugar having a particle size of 300 ⁇ m or more and 425 ⁇ m or less (manufactured by Shimizu Minato Sugar Co., Ltd.) were put into a table type stirring granulator, stirred at 2000 rpm for 30 minutes, and the corners of the crystal were cut to obtain core particles. . Next, 500 g of the obtained core particles are put into a centrifugal tumbling type coating granulator CF granulator, and 10 mass in an aqueous solution having a concentration of 40 mass% in which white sugar (manufactured by Shimizu Minato Sugar Co., Ltd.) is dissolved. A liquid in which% corn starch was suspended was sprayed to form a coating layer.
- spherical particles having a sphericity of 0.95, a friability of 0.4%, a granule hardness of 152 g, and a particle diameter of 355 ⁇ m or more and 500 ⁇ m or less were obtained with a yield of about 72%.
- spherical particles having a sphericity of 0.92, a friability of 0.7%, a granule hardness of 100 g, and a particle diameter of 425 ⁇ m or more and 600 ⁇ m or less were obtained with a yield of about 80%.
- spherical particles having a sphericity of 0.83, a friability of 0.47%, a granule hardness of 260 g, and a particle diameter of 425 ⁇ m or more and 600 ⁇ m or less were obtained with a yield of about 80%.
- Granule hardness After the obtained spherical particles are selected to be 425 ⁇ m or more and 500 ⁇ m or less, the granule hardness is measured using GRANO (Okada Seiko Co., Ltd.) under the conditions of measuring load 1 kg, measuring speed 100 ⁇ m / sec, tip diameter 3 mm ⁇ . did. The granule hardness is an average value of 20 grains.
- C Granule hardness is 100 g or more.
- D Granule hardness is less than 100 g.
- the spherical particles obtained in Examples 3 and 4 are granulated using central core particles with the corners of the crystal grains cut, the sphericity is excellent. Further, the spherical particles obtained in Examples 3 and 4 were excellent in both friability and granule hardness because a liquid was used as the coating layer forming component. On the other hand, in Comparative Example 3 obtained by using crystal grains that do not cut the corners as the central core particles, spherical particles with high sphericity were obtained, but both the surface and the interior had voids, and desirable friability and The granule hardness could not be obtained.
- the present invention relates to a spherical particle and a method for producing the same. According to the method for producing spherical particles of the present invention, spherical particles having a small particle diameter and high sphericity can be obtained. Furthermore, according to the spherical particle of the present invention, a controlled release preparation having preferable release controllability can be obtained.
- Such a controlled-release preparation of the present invention is a hypnotic / sedative, antipyretic analgesic / anti-inflammatory agent, neuropsychiatric agent, autonomic nerve agent, anti-parkinsonian agent, antihistamine, cardiotonic agent, diuretic agent, antihypertensive agent, vasoconstrictor, It can be used in arteriosclerotic agents, antitussive expectorants, vitamins, nourishing tonics, antibiotics, gastrointestinal drugs and the like.
Landscapes
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Manufacturing & Machinery (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
L'invention porte sur un procédé de fabrication d'un grain sphérique caractérisé par le fait qu'il comporte la première étape consistant à arrondir des bords d'un grain cristallin pour former un grain central et la seconde étape consistant à fixer une couche d'enrobage sur la surface du grain central tel que décrit ci-dessus. Selon ce procédé de fabrication, un grain sphérique ayant une petite dimension de grain et une sphéricité élevée peut être obtenu. De plus, l'utilisation de ces grains sphériques permet de produire une préparation à libération entretenue présentant une libération efficacement régulée.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-331675 | 2007-12-25 | ||
JP2007331675A JP2009155215A (ja) | 2007-12-25 | 2007-12-25 | 球形粒及びその製造方法並びに放出制御製剤の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009081716A1 true WO2009081716A1 (fr) | 2009-07-02 |
Family
ID=40801027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/072169 WO2009081716A1 (fr) | 2007-12-25 | 2008-12-05 | Grain sphérique, son procédé de fabrication et procédé pour produire d'une préparation à libération entretenue |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2009155215A (fr) |
WO (1) | WO2009081716A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012066656A1 (fr) * | 2010-11-17 | 2012-05-24 | 日本たばこ産業株式会社 | Granulés à adsorbant supporté et leur procédé de fabrication, filtre à cigarette et cigarette |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03227916A (ja) * | 1990-02-02 | 1991-10-08 | Ss Pharmaceut Co Ltd | 発泡性製剤組成物 |
JP2000128774A (ja) * | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | 薬物を含有する球形微粒子の製法 |
WO2002036168A1 (fr) * | 2000-11-06 | 2002-05-10 | Asahi Kasei Kabushiki Kaisha | Particules cellulosiques destinees a des preparations pharmaceutiques |
JP2005532279A (ja) * | 2002-03-28 | 2005-10-27 | ラブ・ファルマ・オサケユキテュア | 担体粒子を処理するための方法およびその使用 |
JP2006306766A (ja) * | 2005-04-27 | 2006-11-09 | Nikken Chem Co Ltd | テオフィリン徐放性微粒子製剤及びその製造方法 |
JP2007259887A (ja) * | 2006-03-27 | 2007-10-11 | Freunt Ind Co Ltd | 粒子の製造方法および遠心転動造粒装置 |
-
2007
- 2007-12-25 JP JP2007331675A patent/JP2009155215A/ja active Pending
-
2008
- 2008-12-05 WO PCT/JP2008/072169 patent/WO2009081716A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03227916A (ja) * | 1990-02-02 | 1991-10-08 | Ss Pharmaceut Co Ltd | 発泡性製剤組成物 |
JP2000128774A (ja) * | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | 薬物を含有する球形微粒子の製法 |
WO2002036168A1 (fr) * | 2000-11-06 | 2002-05-10 | Asahi Kasei Kabushiki Kaisha | Particules cellulosiques destinees a des preparations pharmaceutiques |
JP2005532279A (ja) * | 2002-03-28 | 2005-10-27 | ラブ・ファルマ・オサケユキテュア | 担体粒子を処理するための方法およびその使用 |
JP2006306766A (ja) * | 2005-04-27 | 2006-11-09 | Nikken Chem Co Ltd | テオフィリン徐放性微粒子製剤及びその製造方法 |
JP2007259887A (ja) * | 2006-03-27 | 2007-10-11 | Freunt Ind Co Ltd | 粒子の製造方法および遠心転動造粒装置 |
Also Published As
Publication number | Publication date |
---|---|
JP2009155215A (ja) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3447042B2 (ja) | 単一物質球形粒の製造方法 | |
JP5461179B2 (ja) | セルロース系微小核粒子及びその製造方法 | |
JP2008007458A (ja) | レイヤリング用核粒子とその製造方法 | |
JP2011063611A (ja) | シロスタゾール製剤 | |
JP2004143071A (ja) | 薬物含有複合粒子の製造方法および薬物含有複合粒子 | |
JP2001163769A (ja) | シロスタゾール製剤 | |
JPH072761B2 (ja) | 微結晶セルロ−ス球形顆粒及びその製造法 | |
WO2002096466A1 (fr) | Composition de medicament | |
JP3349535B2 (ja) | 球形顆粒の製造方法 | |
JP3985907B2 (ja) | フィルムコーティング粒剤の製造方法 | |
Ibrahim | Formulation and evaluation of mefenamic acid sustained release matrix pellets | |
JPH0819003B2 (ja) | 有核顆粒およびその製造法 | |
JP3910939B2 (ja) | 単一物質球形粒、それらを用いた食品、医薬及びそれらの製法 | |
JP3833314B2 (ja) | 発泡性組成物およびその製造方法 | |
Zhai et al. | Gastroretentive extended-release floating granules prepared using a novel fluidized hot melt granulation (FHMG) technique | |
WO2009081716A1 (fr) | Grain sphérique, son procédé de fabrication et procédé pour produire d'une préparation à libération entretenue | |
JP4092587B2 (ja) | 二軸混練機を用いた乾式コーティング | |
US20060115524A1 (en) | Method for preparation of an agglomerate using melt agglomeration | |
EP3815680A1 (fr) | Procédé de traitement pour particules de médicament brut de taille de particule non uniforme | |
JP2009263303A (ja) | 球形顆粒及びその製造方法 | |
Koyanagi et al. | Comparing integrated continuous process “LaVortex®” and conventional batch processes for the pharmaceutical manufacturing of acetaminophen oral dosage formulations: challenges and pharmaceutical properties of the granular and tableted products | |
Kristensen et al. | Development of fast-disintegrating pellets in a rotary processor | |
Krejčová et al. | The influence of drug solubility and particle size on the pellet formulation in a rotoprocessor | |
Bidkar et al. | A review: Factors affecting dissolution of BCS class II drug | |
JP2003012504A (ja) | 薬物含有複合粒子の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08864576 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08864576 Country of ref document: EP Kind code of ref document: A1 |